The offering was fully priced and closed, so no immediate price dislocation is expected. Monitor upcoming clinical trial readouts and the company's ability to execute on commercialization plans, as the extended runway reduces near-term financing risk.
Price Chart
Executive Summary
Pharvaris closed an underwritten public offering of 4,455,863 ordinary shares at $29.68 per share, raising approximately $124 million in net proceeds. The funds will support late-stage clinical programs, U.S. commercialization, and working capital, extending the company's cash runway into the first half of 2028.
Key Facts
- Offering of 4,455,863 ordinary shares (including full exercise of underwriter option for 581,199 additional shares) closed on May 11, 2026.
- Public offering price of $29.68 per share; net proceeds expected to be approximately $124 million.
- Proceeds to fund R&D for late-stage clinical programs, U.S. sales and marketing team expansion, and working capital.
- Company reported $247 million in cash as of March 31, 2026; offering extends runway into first half of 2028.
- Underwriters include Morgan Stanley, Leerink Partners, Cantor Fitzgerald, and Wells Fargo Securities.
Financial Impact
Approximately $124 million in net proceeds raised, representing ~6.2% dilution on ~72 million pre-offering shares outstanding (estimated).
Risk Factors
- Dilution of approximately 6.2% from the offering may pressure near-term share price.
- Execution risk on late-stage clinical programs and U.S. commercialization.
- Biotech sector volatility could impact stock regardless of fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-216957 |
| Document: d134419dex51.htm | 0001193125-26-216957 |
| Document: d134419d6k.htm | 0001193125-26-216957 |
| Document: 0001193125-26-216957-index-headers.html | 0001193125-26-216957 |
| Document: 0001193125-26-216957-index.html | 0001193125-26-216957 |
| Document: 0001193125-26-216957.txt | 0001193125-26-216957 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access